Liposomal nanoparticles can deliver SiRNA against PAX3-FOXO1 efficiently into in vivo ARMS models, delaying tumour initiation/growth, but failed to induce apoptosis [47]. The gene discussed is FOXO1; the disease is alveolar rhabdomyosarcoma.